Natera Inc (NTRA) Stock
Key stats
- Market cap
- $46.38B
- Price / Earnings ratio
- -274.6x
- EPS (TTM)
- -$1.13
- Volume
- Loading
- 52-week high
- $437.41
- 52-week low
- $181.00
Source: third-party data provider, as of November 13, 2026
Compare with NTRA
Recent news
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
NTRA
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
NTRA
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
NTRA
Natera to Report its Third Quarter Results on November 5, 2026
Natera to Report its Third Quarter Results on November 5, 2026
NTRANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.72
- MACD 12/26/9
- -16.97
- EMA 9 of MACD
- -4.73
- MACD histogram
- -12.24
- SMA 50
- $379.91
- Price below SMA 50
- EMA 50
- $368.44
- Price below EMA 50
- SMA 200
- $270.49
- Price above SMA 200
- EMA 200
- $291.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.33 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLY
NTRAMedicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
NTRANatera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
NTRANatera to Report its Third Quarter Results on November 5, 2026
Natera to Report its Third Quarter Results on November 5, 2026
NTRA
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?
NTRA
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
NTRA
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
NTRA
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.
NTRA
Natera Partners With TransCode to Advance Colorectal Cancer Trial
Natera Partners With TransCode to Advance Colorectal Cancer Trial
NTRA
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
NTRANews tone: automated (AI) classification of the article's content, not a price prediction.
About Natera Inc
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven Leonard Chapman | CEO & Director | 1979 |
| Dr. Matthew Rabinowitz Ph.D. | Co-Founder & Executive Chairman | 1973 |
| Mr. Michael B. Brophy M.B.A. | Chief Financial Officer | 1980 |
| Mr. John Fesko | President & Chief Business Officer | 1979 |
| Mr. Solomon Moshkevich M.B.A. | President of Clinical Diagnostics | 1982 |
| Mr. Jonathan Sheena M.Eng. | Co-Founder & Director | 1973 |
| Ms. Olesya A. Anisimova CPA | Chief Accounting Officer | — |
| Mr. Rishi Kacker | Chief Technology Officer | — |
| Mr. Eric A. Evans Ph.D. | Chief Scientific Officer | — |
| Mr. Daniel Rabinowitz L.L.M. | Secretary & Chief Legal Officer | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.72
- MACD 12/26/9
- -16.97
- EMA 9 of MACD
- -4.73
- MACD histogram
- -12.24
- SMA 50
- $379.91
- Price below SMA 50
- EMA 50
- $368.44
- Price below EMA 50
- SMA 200
- $270.49
- Price above SMA 200
- EMA 200
- $291.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $365.00
- Average
- $437.71
- High
- $500.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -21.1 | +4.8 | ||||||||||
| 2022 | -22.6 | -9.7 | -36.8 | -18.1 | -2.3 | -0.1 | +27.3 | +3.1 | -10.7 | +6.6 | -11.9 | -2.6 |
| 2023 | +11.5 | +10.4 | +2.3 | -6.5 | -10.2 | -1.3 | -7.2 | +29.5 | -29.2 | -9.6 | +41.0 | +7.2 |
| 2024 | +6.5 | +26.8 | +2.3 | -0.1 | +13.1 | -0.0 | -5.0 | +14.8 | +11.4 | -4.9 | +35.1 | -6.8 |
| 2025 | +10.2 | -11.9 | -1.2 | +7.3 | +4.2 | +5.1 | -16.8 | +25.0 | -4.9 | +23.1 | +20.5 | -2.2 |
| 2026 | +1.0 | -10.0 | -0.1 | +1.5 | +7.8 | +24.1 | -3.1 | +19.1 | +28.9 | +1.4 | -15.6 |
